A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

被引：0
|
作者：
Andrew H. Ko
Alan P. Venook
Emily K. Bergsland
R. Kate Kelley
W. Michael Korn
Elizabeth Dito
Brian Schillinger
Janet Scott
Jimmy Hwang
Margaret A. Tempero
机构：
[1] University of California at San Francisco Helen Diller Family Comprehensive Cancer Center,
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Bevacizumab; Circulating endothelial cells; Erlotinib; Pancreatic cancer; Phase II; Refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1051 / 1057
页数：6
相关论文
共 50 条
  • [21] Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    T Ioka
    Y Komatsu
    N Mizuno
    A Tsuji
    S Ohkawa
    M Tanaka
    H Iguchi
    A Ishiguro
    M Kitano
    T Satoh
    T Yamaguchi
    K Takeda
    M Kida
    K Eguchi
    T Ito
    M Munakata
    T Itoi
    J Furuse
    C Hamada
    Y Sakata
    British Journal of Cancer, 2017, 116 : 464 - 471
  • [22] Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    Ioka, T.
    Komatsu, Y.
    Mizuno, N.
    Tsuji, A.
    Ohkawa, S.
    Tanaka, M.
    Iguchi, H.
    Ishiguro, A.
    Kitano, M.
    Satoh, T.
    Yamaguchi, T.
    Takeda, K.
    Kida, M.
    Eguchi, K.
    Ito, T.
    Munakata, M.
    Itoi, T.
    Furuse, J.
    Hamada, C.
    Sakata, Y.
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 464 - 471
  • [23] Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
    Van Cutsem, Eric
    Vervenne, Walter L.
    Bennouna, Jaafar
    Humblet, Yves
    Gill, Sharlene
    Van Laethem, Jean-Luc
    Verslype, Chris
    Scheithauer, Werner
    Cosaert, Aijing Shang Jan
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) : 2231 - 2237
  • [24] A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer
    Gomez-Martin, C.
    Camara, J. C.
    Cortes, H.
    Jara, C.
    Gravalos, C.
    Rubio, B.
    Amador, M. L.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Phase II study of PHY906 plus capecitabine (CAP) in pts with gemcitabine-refractory pancreatic cancer (PC) and measurement of cytokines
    Seif, M.
    Li, J.
    Lamb, L.
    Kiley, K.
    Bussom, S.
    Carbone, R.
    Elligers, K.
    Krishnamoorthy, S.
    Liu, S.
    Cheng, Y. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Sarkar, F. H.
    Abruzzese, J. L.
    Kaseb, A. O.
    Javle, M. M.
    Varadhachary, G. R.
    Wolff, R. A.
    El-Rayes, B. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
    Ueno, Makoto
    Ohkawa, Shinichi
    Kobayashi, Noritoshi
    Sugimori, Kazuya
    Kawaguchi, Yoshiaki
    Kobayashi, Satoshi
    Taguri, Masataka
    Yamanaka, Takeharu
    Mine, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [28] Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
    Wolpin, Brian M.
    Hezel, Aram F.
    Abrams, Thomas
    Blaszkowsky, Lawrence S.
    Meyerhardt, Jeffrey A.
    Chan, Jennifer A.
    Enzinger, Peter C.
    Allen, Brittany
    Clark, Jeffrey W.
    Ryan, David P.
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 193 - 198
  • [29] Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
    Moon Jae Chung
    Huapyong Kang
    Ho Gak Kim
    Jong Jin Hyun
    Jun Kyu Lee
    Kwang Hyuck Lee
    Myung Hwan Noh
    Dae Hwan Kang
    Sang Hyub Lee
    Seungmin Bang
    World Journal of Gastrointestinal Oncology, 2018, (12) : 505 - 515
  • [30] Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    Villa, Eugenio
    Cereda, Stefano
    Mazza, Elena
    Vigano, Maria Grazia
    Vitali, Giordano
    Rognone, Alessia
    Di Carlo, Valerio
    Reni, Michele
    ANNALS OF ONCOLOGY, 2007, 18 : 15 - 15
12345